Abstract
Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Current Drug Delivery
Title: Particulate and Vesicular Drug Carriers in the Management of Tuberculosis
Volume: 3 Issue: 1
Author(s): Rachna Rastogi, Yasmin Sultana, Asgar Ali and Mohammed Aqil
Affiliation:
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Abstract: Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Export Options
About this article
Cite this article as:
Rastogi Rachna, Sultana Yasmin, Ali Asgar and Aqil Mohammed, Particulate and Vesicular Drug Carriers in the Management of Tuberculosis, Current Drug Delivery 2006; 3 (1) . https://dx.doi.org/10.2174/156720106775197448
DOI https://dx.doi.org/10.2174/156720106775197448 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Biology of Bacterial Secretion Systems in Gram-Negative Pathogens- Potential for New Drug Targets
Infectious Disorders - Drug Targets Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents Synthetic Polyacrylate Polymers as Particulate Intranasal Vaccine Delivery Systems for the Induction of Mucosal Immune Response
Current Drug Delivery Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Natural Compounds for Overcoming Multidrug Resistance in Mycobacteria
Recent Patents on Biotechnology Cholestasis During Pregnancy: Aetiopathogenesis, Foetal-Maternal Repercussions and Pharmacological Treatments
Current Women`s Health Reviews Meet the Editorial Board Member
Current Pharmaceutical Biotechnology Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry Editorial [ The Reversal of Drug Resistance from Bacteria to Cancer Cells Part - I Guest Editor: Joseph Molnar ]
Current Drug Targets Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry The Expanding Role of Tumor Necrosis Factor-α Inhibitors in the Management of Rheumatic Diseases
Medicinal Chemistry Reviews - Online (Discontinued) Recent Patents on DNA Sequences and Diagnostic Methods for the Identification and Strain Differentiation of Mycobacterium Tuberculosis
Recent Patents on DNA & Gene Sequences The State of the Art in Anti-Malarial Drug Discovery and Development
Current Topics in Medicinal Chemistry Identification of Novel Cytotoxic T Lymphocyte Epitopes of Drug- Resistance Related Protein InhA from Mycobacterium tuberculosis
Protein & Peptide Letters Microwave-Assisted Synthesis of Pyrazinamide Derivatives: The Coupling Reaction of 3-Chloropyrazine-2-Carboxamide and Ring-Substituted Anilines
Current Organic Synthesis Correlates of Patient Retention in HIV Care and Treatment Programs in Nigeria
Current HIV Research Environmental Exposure, and Other Behavioral Risk Factors in Breast Cancer
Current Cancer Therapy Reviews Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design